Last updated: July 6, 2026
Executive summary
Amneal Pharmaceuticals LLC v. Alembic Pharmaceuticals Ltd., 1:26-cv-00798, is a federal Hatch-Waxman patent dispute filed in 2026 between (i) Amneal as the reference-listed drug (RLD) or NDA holder-side party and (ii) Alembic Pharmaceuticals as a generic applicant party. The case is a standard § 271(e)(2) “Orange Book-listed patent” litigation track, but no enforceable, case-specific litigation particulars (asserted patents, claims, paragraph-IV certifications, settlement terms, or briefing posture) are included in the provided prompt. Without those record-level facts, a complete and accurate litigation summary and patent-analytics assessment cannot be produced.
Litigation summary and analysis for Amneal Pharmaceuticals LLC v. Alembic Pharmaceuticals Ltd. (1:26-cv-00798)
No case-specific litigation details are available in the input to support a complete summary or analysis.
What patents are asserted in Amneal v. Alembic (1:26-cv-00798)?
No asserted-patent list is included in the input.
Which Orange Book patents are at issue?
No Orange Book patent numbers, titles, or listed expiration dates are included in the input.
Are the asserted claims method-of-use, formulation, or manufacturing claims?
No claim type breakdown is included in the input.
What type of infringement claim does the complaint allege under 35 U.S.C. § 271(e)(2)?
No complaint theory or certification basis is included in the input.
What is the paragraph IV basis, and which certification(s) are challenged?
No paragraph-IV certification language or certification matrix is included in the input.
Are there counterclaims or antitrust or inequitable-conduct allegations?
No counterclaims or misconduct allegations are included in the input.
What procedural posture is the case in as of filing in 2026?
No docket events, deadlines, or posture (e.g., T.R.O./preliminary injunction motions, Markman scheduling, expert disclosures) are included in the input.
Has the court entered a scheduling order or set a trial date?
No scheduling or trial date is included in the input.
Have any patents been dropped, narrowed, or mooted by settlement or stipulation?
No stipulation or narrowing events are included in the input.
What are the key litigation events and dates for 1:26-cv-00798?
The prompt provides only the case number and filing year; no PACER/docket event dates are included in the input.
Complaint filing date and parties
The prompt states case caption and number only: Amneal Pharmaceuticals LLC v. Alembic Pharmaceuticals Ltd., 1:26-cv-00798. No filed date is provided in the input.
Any amended complaints or amended answers
No amendments are included in the input.
Markman, expert, and dispositive motion timeline
No such events are included in the input.
How do the asserted patents affect the generic launch timeline for Alembic?
No asserted-patent list, listed expiration dates, or exclusivity triggers are included in the input.
When does exclusivity or the last-to-expire patent end?
No exclusivity or expiration dates are included in the input.
What launch workarounds exist if a formulation or method claim is found invalid or not infringed?
No claim-level findings or injunction risk characterization is possible without asserted claims and theories.
What settlement outcomes are typical in Amneal v. Alembic-style Hatch-Waxman cases?
No settlement agreement is included in the input.
Is there a court-ordered settlement class or consent injunction?
No consent injunction or class settlement terms are included in the input.
Are there “180-day exclusivity” or non-monetary agreement terms implicated?
No generic first-filer status or exclusivity terms are included in the input.
Which courts and jurisdictions control the substantive patent issues in 1:26-cv-00798?
No court division or judge assignment is included in the input.
Is the case in a district with specific standing or venue doctrines?
No venue or judge-specific practice details are included in the input.
How strong is Amneal’s patent estate in this case?
No patent numbers, claim constructions, prior art, prosecution history, or infringement contentions are included in the input.
Are the patents likely to face obviousness, lack of written description, or enablement challenges?
No invalidity contentions are included in the input.
What is the likely claim construction risk?
No terms or claim language is included in the input.
Patent estate and Orange Book context (what’s missing prevents a complete analysis)
A litigation analysis depends on: (i) the specific Orange Book patents asserted, (ii) the paragraph-IV certifications being litigated, (iii) the RLD drug and application number being referenced, and (iv) the generic product description in the complaint or ANDA. None of these are present in the input.
Key Takeaways
- The prompt provides the case caption and docket number only.
- A case-specific litigation summary requires asserted patents, infringement/invalidity theories, procedural posture, and docket dates, none of which are included in the input.
- No accurate patent-timeline, injunction-risk, or settlement-outcome analysis can be completed from the provided information.
FAQs
1) What is the basis for 1:26-cv-00798 under Hatch-Waxman?
No complaint basis or asserted certifications are included in the input.
2) Does Amneal or Alembic seek a preliminary injunction?
No motion practice or request for preliminary injunctive relief is included in the input.
3) Which Orange Book patents are challenged in the case?
No patent numbers or Orange Book listings are included in the input.
4) Has the court issued a claim construction (Markman) order?
No Markman or claim construction order is included in the input.
5) Is there a settlement agreement or dismissal filed in 1:26-cv-00798?
No settlement agreement, dismissal, or stipulation is included in the input.
References (APA)
No cited sources are available from the provided input.
